By means of drug inhibition and CRISPR/Cas9 knockout of IDH1mut, our previous studies have implicated IDH mutation in chondrosarcoma tumorigenicity, in vitro and in vivo [22, 24]. The gene discussed is IDH1; the disease is chondrosarcoma.